Vical wins orphan drug status

The FDA has granted orphan drug status to Vical's vaccine for the herpes virus cytomegalovirus. A mid-stage trial is planned for the second part of the year among bone marrow donors and recipients. The virus occurs in about 30 percent to 60 percent of bone marrow and solid organ transplant patients.

- read this article from the AP for more

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.